Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Keryx Initiates Zerenex Phase 3 Registration Program
The initiation of this study marks the commencement of the Keryx’s Phase 3 registration program for Zerenex, which is being conducted in accordance with a special protocol assessment
The initiation of this study marks the commencement of the Keryx’s Phase 3 registration program for Zerenex, which is being conducted in accordance with a special protocol assessment
The double-blind, placebo-controlled clinical study was conducted by researchers at the University of Cincinnati – College of Medicine. The study, entitled ‘Improved cognitive-cerebral function in older adults with
Novartis will provide Polyphor with an upfront payment, research funding and milestone payments as candidate molecules progress through the drug discovery process, preclinical and clinical development and onto
As part of the agreement, Meda is expected to take over full responsibility for development and commercialisation of the compound. Flupirtine is currently in Phase II development for
Amylin Pharmaceuticals, Eli Lilly and Alkermes have claimed that Bydureon is the proposed brand name for exenatide once weekly. It is an investigational, extended-release medication for type 2
IncellDx claimed that the HPV OncoTect E6, E7 mRNA test provides quantification of the over expression of E6/E7 mRNA in each cell, as well as the total proportion
Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies. Hsiao Lieu, VP of clinical
Stem and regenerative cells were prepared and made available at the point-of-care using the Celution System, the cell processing device developed by trial sponsor Cytori Therapeutics. Cytori said
The data are expected to be presented during a poster session at the 29th Annual Scientific Meeting of the American Pain Society (APS), and are supported by PriCara,
The published study results show that one year after a stenting procedure, patients treated with Abott’s Xience V Everolimus Eluting Coronary Stent System were less likely to have